ArticleEuropean journal of nuclear medicine and molecular imaging2026
The predictive role of [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[¹⁷⁷Lu]Lu-PSMA RLT represents an effective option for advanced mCRPC. SPECT/CT allows the assessment of biodistribution and lesion-level tracer accumulation. We aimed to determine whether semiquantitative RLT SPECT/CT parameters could predict response on a lesion level.
methodsWe retrospectively considered consecutive mCRPC patients who, between February 2022 and January 2026, received minimum two [¹⁷⁷Lu]Lu-PSMA-617 cycles at Messina and Genova Universities, with SPECT/CT at the 1st RLT, including whole PSMA-positive disease. Each [¹⁷⁷Lu]Lu-PSMA-617-positive lesion was semiautomatically segmented using MIM through a 40% threshold to extract SUVmax, SUVmean, Total Lesion Volume (TLV), and Total Lesion Activity (TLA=SUVmean×TLV). Each lesion's semiquantitative parameter was correlated with the single-lesion response at the last RLT cycle, classified as progressive or non-progressive (complete/partial response, stable disease) according to cut-offs from qualitative RECIP 1.0 and quantitative PPP criteria. ROC curves were used to determine the best cutoffs.
resultsWe included 23 mCRPC patients for a total of 290 lesions: 249 osteomedullary, 34 lymph nodal, and 7 visceral. At the last cycle, 60 out of 290 lesions progressed, while 230 out of 290 remained stable/responded to RLT. 1st cycle [¹⁷⁷Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters were significantly higher in non-PD than in PD lesions (p < 0.001 for TLA, SUVmax, SUVmean; p = 0.008 for TLV). On ROC analysis, TLA reached an AUC of 0.854 (best cut-off = 61.7), SUVmax 0.843 (best cut-off = 11.8), SUVmean 0.838 (best cut-off = 6), and TLV 0.612 (best cut-off = 7.05mL), respectively.
conclusionOur preliminary findings suggest that 1st cycle [¹⁷⁷Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters, especially when reflecting PSMA-expression, may serve as promising early predictors of the single-lesion response to RLT.
Indexed as
Identifiers
42156554What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.